Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for Aflibercept (excluding 114.3 mg/ml)

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Nov 03, 2027 · 432 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Aflibercept, ausgenommen 114,3 mg/ml, ATC S01LA05

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice uses an open-house model while the form type is 'open'; although the buyer explains this, the procedural fra...

Paper submissions are only timely if the scan is sent in advance and the original paper documents arrive by the 10th of...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Non-exclusive rebate agreements for the medicinal product Aflibercept, excluding 114.3 mg/ml, ATC S01LA05.
  • Supply contract for pharmaceutical products under an open-house model.
Pokaż pełne podsumowanie

This is an open-house pharmaceutical supply arrangement by AOK Bayern for Aflibercept (excluding 114.3 mg/ml, ATC S01LA05). It is not a competitive award procedure in the usual sense: the buyer states that any pharmaceutical company meeting the stated suitability requirement can join on identical, non-negotiable terms. The contract period runs from 2026-01-01 to 2027-12-31, with contract entry possible until 2027-11-03. Submission is via DTVP electronic portal with qualified electronic signature or by signed paper originals in duplicate. No contract value is stated.

Ryzyka

The notice uses an open-house model while the form type is 'open'; although the buyer explains this, the procedural fra...

Paper submissions are only timely if the scan is sent in advance and the original paper documents arrive by the 10th of...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • The contract and the annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for Aflibercept (excluding 114.3 mg/ml)

Open-house supply arrangement for pharmaceutical rebate agreements concerning Aflibercept, excluding 114.3 mg/ml, ATC S01LA05. The lot is described as a non-exclusive, identical, non-individually negotiable contract offered to all interested pharmaceutical companies meeting the suitability requirement. Source: structured data and notice text.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Dec 2025 - Dec 2027

Kategoria

Pharmaceutical products

Termin

Deadline Nov 03, 2027

Szczegóły zamówienia

Data publikacji
16 Nov 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
760140-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30